🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today we reported financial results and business highlights for the third quarter of 2023. Link: bit.ly/3QPttNU #hookipapharma #arenavirus #immunooncology #cancer #cancerresearch #$HOOK

We are very pleased to announce the FDA has cleared our IND application for HB-500 a novel arenaviral therapeutic vaccine for the treatment of HIV. A Phase 1 trial will commence in the first half of 2024. Link: bit.ly/3NerMaH #hookipapharma #arenavirus #HIV #FDA

#WorldAIDSDay is an opportunity to reflect on the tremendous progress that has been made in addressing the global burden of HIV/AIDS. HOOKIPA is committed to furthering research to help #endAIDS. #HIV #hookipapharma HIV.gov

To advance our ongoing Gilead-partnered HIV therapeutic vaccine program, Gilead buys 15 million shares of $HOOK at $1.4167 per share under amended stock purchase agreement. #hookipapharma #HIV #arenavirus ir.hookipapharma.com/news-releases/…

HOOKIPA Appoints Mark Winderlich, PhD, as Chief Development Officer to Lead Clinical Research and Development Organization. #hookipapharma #arenavirus #immunooncology #infectiousdiseases ir.hookipapharma.com/news-releases/…

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs #hookipapharma #arenavirus #immunooncology #infectiousdiseases ir.hookipapharma.com/news-releases/…

HOOKIPA Pharma's CFO, Reinhard Kandera will present at the Leerink Partners Global Biopharma Conference on March 13, at 9:20 a.m. ET—use the link to register $hook #hookipapharma #arenavirus #immunooncology #infectiousdiseases wsw.com/webcast/leerin…

April is Head and Neck Cancer Awareness Month. HOOKIPA encourages you and your loved ones to get screened today. Early detection and diagnosis is crucial to successful treatment. Join HOOKIPA and help fight #headandneckcancer! #hookipapharma Head and Neck Cancer Alliance

Join us! HOOKIPA to host an investor call on April 25, to discussHB-200 pivotal clincal trial design and protocol. Trial alignment with FDA. Company receives PRIME designation from EMA. $HOOK #hookipapharma Register here: edge.media-server.com/mmc/p/2xv65k75

HOOKIPA announces FDA clearance of its IND application for the treatment of KRAS-mutated tumors; Achieves $10M milestone payment. #KRAS $HOOK ir.hookipapharma.com/news-releases/…

HOOKIPA announces pivotal Phase 2/3 trial design for HB-200; potential for accelerated approval submission following Phase 2 primary analysis based on ORR; Investor call today; ASCO presentation with ~40 patients #headandneckcancer #OPSCC $HOOK ir.hookipapharma.com/news-releases/…

HOOKIPA to participate in upcoming investor conferences. Citizens JMP Life Sciences Conference on May 14 at 11:00am ET and RBC Global Healthcare Conference on May 15 at 8:30am ET. $HOOK Register here: ir.hookipapharma.com/events

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights $HOOK Read the release: ir.hookipapharma.com/news-releases/…

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting #ASCO24 $HOOK ir.hookipapharma.com/news-releases/…

Join us! HOOKIPA to host an investor call on June 4 to discuss updated HB-200Phase 2 clinical data including promising preliminary progression free survival data. $HOOK #hookipapharma #ASCO2024 Register here: edge.media-server.com/mmc/p/5w8hx86r

Join the HOOKIPA team at #ASCO24 to discuss three accepted abstracts presenting data from HOOKIPA programs including presentations during the Head and Neck Cancer oral abstract and rapid oral abstract sessions. ir.hookipapharma.com/news-releases/…

HOOKIPA Announces Updated Ph2 Clinical Data at the #ASCO24 Annual Meeting; Encouraging clinical activity; Preliminary PFS: 16.3 months for patients with CPS≥20 or higher. Investor call today. $HOOK #hookipapharma Press Release: ir.hookipapharma.com/news-releases/…

HOOKIPA announces first person dosed in Phase 1b clinical trial of HB-500 for the treatment of HIV; Achieves $5MM milestone #hookipapharma #HIV $HOOK Press Release: ir.hookipapharma.com/news-releases/…

HOOKIPA announces the appointment of Directors Dr. Malte Peters as CEO and Terry Coelho as CFO, effective July 22, 2024. They will both retain their positions on the Board of Directors (“Board”) $HOOK Press Release: ir.hookipapharma.com/news-releases/…

HOOKIPA Pharma Reports Q224 Earnings: New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q424 $HOOK Press Release: ir.hookipapharma.com/news-releases/…